



October 30, 2017

AlloSure data will be presented at ASN

CareDx further bolsters clinical evidence

BRISBANE, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that new data regarding the clinical utility of AlloSure will be presented at the American Society of Nephrology Annual Meeting (ASN) taking place in New Orleans from November 2-5, 2017.

In the beginning of October CareDx launched AlloSure following completion of the MoIDX Technical Assessment process and subsequent Medicare coverage. AlloSure marks a new path in the surveillance of Kidney Transplant patients by directly monitoring the health of the organ through the measurement of donor-derived cell-free DNA.

Suphamai Bunnapradist, MD at UCLA will be presenting "Donor-Derived Cell-Free DNA Improves DSA-Informed Diagnosis of ABMR in Kidney Transplant Patients" at a session covering diagnosis and treatment of kidney transplantation on November 3, 2017. The presentation will discuss the combined use of donor-derived cell-free DNA measurement by AlloSure and detection of donor-specific antibodies (DSA) to diagnose active antibody mediated rejection. In particular, the combination of positive AlloSure and positive DSA have a much higher positive predictive value for antibody mediated rejection than previous use of DSA positivity alone.

"In addition to the published data describing the use of AlloSure by itself to identify rejection, the data we are presenting at ASN highlights the potential to use AlloSure with DSA to identify antibody mediated rejection specifically," said Stanley Jordan, MD at Cedar Sinai and lead author on the abstract that will be presented at ASN. "We have incorporated AlloSure into our clinical practice and have already experienced this clinical utility in detecting rejection earlier."

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding the potential to use AlloSure with DSA to identify antibody mediated rejection specifically. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017 and the periodic reports that we have subsequently filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
[sking@caredx.com](mailto:sking@ caredx.com)

Investor Relations

David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com

Source: CareDx, Inc.

News Provided by Acquire Media